Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shields

Showing results (301-310 of 413) with videos related to

Pageof 42
Sort By:
Jac-Antimicrobial Resistance|September 6, 2024
Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing <i>Escherichia coli</i> bloodstream isolate exhibiting reduced susceptibility to both agents at baselineGhady Haidar, Ellen G Kline, Georgios D Kitsios, et al.
Cells|March 13, 2024
Harnessing the Diversity of <i>Burkholderia</i> spp. Prophages for Therapeutic PotentialHayley R Nordstrom, Marissa P Griffith, Vatsala Rangachar Srinivasa, et al.
Plos One|March 8, 2017
Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteriaRyan K Shields, Rohit Anand, Lloyd G Clarke, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2016
Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter SpeciesGhady Haidar, Ammar Alkroud, Shaoji Cheng, et al.
The Journal of Infectious Diseases|May 30, 2025
Functional genomics of antibiotic susceptibility in Enterococcus faecalis from infective endocarditisYanhong Li, Madison E Stellfox, Kirsten M Evans, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2026
Ceftazidime-avibactam resistance evolution in <i>Pseudomonas aeruginosa</i> and implications for cross-resistance to other novel β-lactamsAva J Dorazio, Ellen G Kline, Kevin M Squires, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Harnessing the diversity of <i>Burkholderia</i> spp. prophages for therapeutic potentialHayley R Nordstrom, Marissa P Griffith, Vatsala Rangachar Srinivasa, et al.
Pharmacotherapy|May 15, 2025
Pharmacokinetic and pharmacodynamic evaluation of sulbactam-durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complexWesley D Kufel, Nabil Zeineddine, Aliaa Fouad, et al.
Antimicrobial Agents and Chemotherapy|July 5, 2017
Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant PatientsRyan M Rivosecchi, Cornelius J Clancy, Ryan K Shields, et al.
The Journal of Antimicrobial Chemotherapy|August 29, 2022
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniaeVincent H Tam, Paul R Merlau, Cole S Hudson, et al.
Pageof 42

Showing results (301-310 of 413) with videos related to

Sort By:
Pageof 42
Jac-Antimicrobial Resistance|September 6, 2024
Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing <i>Escherichia coli</i> bloodstream isolate exhibiting reduced susceptibility to both agents at baselineGhady Haidar, Ellen G Kline, Georgios D Kitsios, et al.
Cells|March 13, 2024
Harnessing the Diversity of <i>Burkholderia</i> spp. Prophages for Therapeutic PotentialHayley R Nordstrom, Marissa P Griffith, Vatsala Rangachar Srinivasa, et al.
Plos One|March 8, 2017
Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteriaRyan K Shields, Rohit Anand, Lloyd G Clarke, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2016
Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter SpeciesGhady Haidar, Ammar Alkroud, Shaoji Cheng, et al.
The Journal of Infectious Diseases|May 30, 2025
Functional genomics of antibiotic susceptibility in Enterococcus faecalis from infective endocarditisYanhong Li, Madison E Stellfox, Kirsten M Evans, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2026
Ceftazidime-avibactam resistance evolution in <i>Pseudomonas aeruginosa</i> and implications for cross-resistance to other novel β-lactamsAva J Dorazio, Ellen G Kline, Kevin M Squires, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Harnessing the diversity of <i>Burkholderia</i> spp. prophages for therapeutic potentialHayley R Nordstrom, Marissa P Griffith, Vatsala Rangachar Srinivasa, et al.
Pharmacotherapy|May 15, 2025
Pharmacokinetic and pharmacodynamic evaluation of sulbactam-durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complexWesley D Kufel, Nabil Zeineddine, Aliaa Fouad, et al.
Antimicrobial Agents and Chemotherapy|July 5, 2017
Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant PatientsRyan M Rivosecchi, Cornelius J Clancy, Ryan K Shields, et al.
The Journal of Antimicrobial Chemotherapy|August 29, 2022
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniaeVincent H Tam, Paul R Merlau, Cole S Hudson, et al.
Pageof 42